AIPLA Diversity in IP Law Committee: Navigating the State of DEI in 2025

On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry.

Arlington, VA. May 12, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the USPTO on its Supplemental Guidance for Examination of Design Patent Applications Related to Computer-Generated Interfaces and Icons, issued on March 13, 2026.

Arlington, VA. May 1, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments in response to the U.S. Copyright Office’s Notice of Proposed Rulemaking on adjustments to its fee schedule.

Arlington, VA. April 17, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the Enlarged Board of Appeal’s 11 March 2026 preliminary opinion in G 1/25, addressing whether patent descriptions must be adapted following claim amendments.

Arlington, VA — April 17, 2026 — The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the U.S. Court of Appeals for the Federal Circuit in Range of Motion Products, LLC v. Armaid Company Inc., No. 23-2427, supporting rehearing and rehearing en banc. AIPLA urges the Court to restore clarity to design patent law by (1) reaffirming that Gorham v. White (1871) provides the sole governing test for infringement and forecloses any separate “plainly dissimilar” threshold, and (2) confirming that claim construction may not be used to exclude any visual portions of the overall claimed design.